AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36122564 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary or nutritional adjustments
Number of subjects: 115
Study 36122564 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoption of at least one lifestyle factor
Number of subjects: 115
Study 36122564 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoption of lifestyle factors in all three domains
Number of subjects: 115
Study 32141724 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroscience-informed auditory training (AT) exercises
Number of subjects: 84
Study 33825677 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention with follow-up visits
Number of subjects: 0
Study 33825677 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 0
Study 33825677 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 0
Study 33933265 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet gel application in tubularized incised plate (TIP) repair
Number of subjects: 30
Study 33933265 — intervention group
Group type: COMPARATOR
Intervention: TIP repair without autologous platelet gel
Number of subjects: 30
Study 32016111 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (12 sessions)
Number of subjects: 128
Study 32016111 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal magnetic innervation (12 sessions)
Number of subjects: 128
Study 32016111 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapeutic intervention)
Number of subjects: 128
Study 32447370 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine
Number of subjects: 913
Study 32447370 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 913
Study 32447370 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline carriage density
Number of subjects: 913
Study 35830848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon infusion (2 g, Cinnamomum sp.)
Number of subjects: 21
Study 35830848 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 21
Study 33016219 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived social support via belonging affirmation
Number of subjects: 0
Study 33016219 — intervention group
Group type: COMPARATOR
Intervention: No perceived social support
Number of subjects: 0
Study 36318788 — intervention group
Group type: EXPERIMENTAL
Intervention: RMST-based decision aid (n=49)
Number of subjects: 102
Study 36318788 — intervention group
Group type: COMPARATOR
Intervention: Conventional decision aid (n=53)
Number of subjects: 102
Study 33665813 — intervention group
Group type: EXPERIMENTAL
Intervention: ZnO‐NP‐coated socks
Number of subjects: 148
Study 33665813 — intervention group
Group type: COMPARATOR
Intervention: Uncoated socks
Number of subjects: 148
Study 33665813 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ZnO‐NP-coated and uncoated socks)
Number of subjects: 148
Study 32212012 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin at a prophylactic dose (SHPD) - enoxaparin 4000 U/day
Number of subjects: 383
Study 32212012 — intervention group
Group type: EXPERIMENTAL
Intervention: SHPD reduction/discontinuation
Number of subjects: 383
Study 35285398 — intervention group
Group type: COMPARATOR
Intervention: Virtual home visits
Number of subjects: 30
Study 35285398 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person home visits
Number of subjects: 30
Study 34312872 — intervention group
Group type: EXPERIMENTAL
Intervention: Early orthodontic therapy (OT) at 4 weeks post surgery
Number of subjects: 43
Study 34312872 — intervention group
Group type: COMPARATOR
Intervention: Late orthodontic therapy (OT) at 6 months post surgery
Number of subjects: 43
Study 34312872 — intervention group
Group type: EXPERIMENTAL
Intervention: Early orthodontic therapy (OT)
Number of subjects: 43
Study 34312872 — intervention group
Group type: COMPARATOR
Intervention: Late orthodontic therapy (OT)
Number of subjects: 43
Study 35192411 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib 75 mg orally twice daily for approximately 5 weeks
Number of subjects: 400
Study 35192411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 35192411 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib
Number of subjects: 400
Study 33522954 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy low-carbohydrate diet (< 40 g of net carbohydrates for the first 3 months and < 40 to 60 net grams for months 3 to 6)
Number of subjects: 150
Study 33522954 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 150
Study 33522954 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy low-carbohydrate diet
Number of subjects: 150
Study 616038894 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein and zeaxanthin supplementation
Number of subjects: 5
Study 616038894 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 5
Study 35575839 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week distance-delivered social skills program, sessions offered twice a week for 90 min
Number of subjects: 24
Study 35575839 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 24
Study 33150640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT‐E)
Number of subjects: 130
Study 33150640 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Eating Disorders (IPT‐ED)
Number of subjects: 130
Study 35688173 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg IV every 2 weeks) plus Cabozantinib (40 mg orally once daily)
Number of subjects: 651
Study 35688173 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (50 mg orally once daily)
Number of subjects: 651
Study 35688173 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus Cabozantinib
Number of subjects: 651
Study 35688173 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 651
Study 34331676 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics used concurrently with antibiotics (Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis) for 1 week
Number of subjects: 55
Study 34331676 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics used after antibiotics for 1 week
Number of subjects: 55
Study 34331676 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic treatment (piperacillin–tazobactam) for 1 week
Number of subjects: 55
Study 34331676 — intervention group
Group type: COMPARATOR
Intervention: No intervention (antibiotic therapy only)
Number of subjects: 55
Study 32727497 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic bone marrow sparing intensity modulated radiotherapy (PBMS‐IMRT)
Number of subjects: 164
Study 32727497 — intervention group
Group type: COMPARATOR
Intervention: Control group (weekly cisplatin with IMRT)
Number of subjects: 164
Study 36436774 — intervention group
Group type: EXPERIMENTAL
Intervention: Biplane thrombectomy
Number of subjects: 197
Study 36436774 — intervention group
Group type: COMPARATOR
Intervention: Monoplane thrombectomy
Number of subjects: 197
Study 33380155 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care intervention (neuropalliative care consultations with a multidisciplinary palliative team)
Number of subjects: 103
Study 33380155 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 103
Study 35086790 — intervention group
Group type: EXPERIMENTAL
Intervention: OligoG (1050 mg daily)
Number of subjects: 14
Study 35086790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 33524488 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 8014
Study 33524488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8014
Study 33524488 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline and Placebo
Number of subjects: 8014
Study 32723265 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy and an oral integrator (Micronil Dol®) composed of acetyl‐L‐carnitine, α‐lipoic acid, quercetin, bromelain, pantothenic acid, C and B1 and B2 and B6 and B12 vitamins
Number of subjects: 36
Study 32723265 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 36
Study 33258426 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculated with a 3 mm diameter PDA plug from the colony margin of Neofusicoccum batangarum
Number of subjects: 16
Study 33258426 — intervention group
Group type: COMPARATOR
Intervention: Control plants treated with PDA plugs only
Number of subjects: 16
Study 36122263 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral PKP
Number of subjects: 72
Study 36122263 — intervention group
Group type: COMPARATOR
Intervention: Bilateral PKP
Number of subjects: 72
Study 34424730 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly rifapentine‐isoniazid for 3 months (n=3610)
Number of subjects: 4014
Study 34424730 — intervention group
Group type: COMPARATOR
Intervention: Daily isoniazid for 6 months (n=404)
Number of subjects: 4014
Study 34424730 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine‐isoniazid regimen given annually for 2 years (n=1808)
Number of subjects: 4014
Study 34424730 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine‐isoniazid regimen given once (n=1802)
Number of subjects: 4014
Study 35314388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional macular atrophy (ILMA)
Number of subjects: 532
Study 35314388 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperreflective material (HRM)
Number of subjects: 532
Study 35314388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraretinal fluid (IRF)
Number of subjects: 532
Study 35314388 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal fluid (SRF)
Number of subjects: 532
Study 35314388 — intervention group
Group type: EXPERIMENTAL
Intervention: Pigment epithelial detachment (PED)
Number of subjects: 532
Study 35314388 — intervention group
Group type: EXPERIMENTAL
Intervention: Disorganization of outer retinal layers (DROL)
Number of subjects: 532
Study 35314388 — intervention group
Group type: EXPERIMENTAL
Intervention: Best corrected visual acuity (BCVA)
Number of subjects: 532
Study 35314388 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ILMA
Number of subjects: 532
Study 35314388 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of HRM
Number of subjects: 532
Study 35314388 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveal pigment epithelial detachment (PED)
Number of subjects: 532
Study 35314388 — intervention group
Group type: EXPERIMENTAL
Intervention: Low luminance visual acuity (LLVA)
Number of subjects: 532
Study 33626568 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants reminded of the pandemic before reporting Trump support
Number of subjects: 1763
Study 33626568 — intervention group
Group type: EXPERIMENTAL
Intervention: Republicans concerned about the pandemic
Number of subjects: 1763
Study 32470440 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0
Study 32470440 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide with rituximab
Number of subjects: 0
Study 35687710 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga for 60 minutes
Number of subjects: 0
Study 35687710 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity exercise for 60 minutes
Number of subjects: 0
Study 35687710 — intervention group
Group type: COMPARATOR
Intervention: Group-based health-and-wellness education for 45 minutes
Number of subjects: 0
Study 33599143 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical mitral valve replacement
Number of subjects: 2812
Study 33599143 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical aortic valve replacement (AVR)
Number of subjects: 2812
Study 33599143 — intervention group
Group type: COMPARATOR
Intervention: Bioprosthetic mitral valve replacement
Number of subjects: 2812
Study 33599143 — intervention group
Group type: COMPARATOR
Intervention: Bioprosthetic aortic valve replacement (AVR)
Number of subjects: 2812
Study 32773581 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of aspirin daily during pregnancy
Number of subjects: 90
Study 32773581 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily during pregnancy
Number of subjects: 90
Study 35590177 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent assessment conditions
Number of subjects: 235
Study 35590177 — intervention group
Group type: COMPARATOR
Intervention: Infrequent assessment conditions
Number of subjects: 235
Study 35852582 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 0
Study 35852582 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study 35852582 — intervention group
Group type: EXPERIMENTAL
Intervention: RDN and Sham control
Number of subjects: 0
Study 32326796 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (aspirin plus ticagrelor)
Number of subjects: 352
Study 32326796 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (aspirin plus clopidogrel)
Number of subjects: 352
Study 32326796 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 352
Study 32326796 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor and Clopidogrel
Number of subjects: 352
Study 33512618 — intervention group
Group type: EXPERIMENTAL
Intervention: audio format
Number of subjects: 124
Study 33512618 — intervention group
Group type: COMPARATOR
Intervention: unimodal formats (text, audio, pictures)
Number of subjects: 124
Study 33512618 — intervention group
Group type: COMPARATOR
Intervention: multimodal format (text/audio with pictures)
Number of subjects: 124
Study 33243806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus erlotinib
Number of subjects: 0
Study 33243806 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus erlotinib
Number of subjects: 0
Study 33243806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus erlotinib (price reduction scenario)
Number of subjects: 0
Study 33243806 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib (price reduction scenario)
Number of subjects: 0
Study 34863009 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermentation with Lactiplantibacillus plantarum CRL2211 and Weissella paramesenteroides CRL2182 for 24 hours at 37°C
Number of subjects: 0
Study 34863009 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented doughs
Number of subjects: 0
Study 34863009 — intervention group
Group type: COMPARATOR
Intervention: Other processing methods (soaking, germination, cooking)
Number of subjects: 0
Study 34895292 — intervention group
Group type: COMPARATOR
Intervention: Non-antibacterial therapeutic clothing (Group A)
Number of subjects: 165
Study 34895292 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan-based therapeutic clothing (Group B)
Number of subjects: 165
Study 34895292 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-based therapeutic clothing (Group C)
Number of subjects: 165
Study 34895292 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 165
Study 35854255 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric cycling (CONC) for 12 weeks
Number of subjects: 100
Study 35854255 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric cycling (ECC) for 12 weeks
Number of subjects: 100
Study 35854255 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined eccentric/concentric cycling (ECC/CONC) for 12 weeks
Number of subjects: 100
Study 35854255 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular adaptations regulating muscle growth
Number of subjects: 100
Study 34259404 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular intradermal needling
Number of subjects: 90
Study 34259404 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point sticking
Number of subjects: 90
Study 34259404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 34851219 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐defense victim
Number of subjects: 505
Study 34851219 — intervention group
Group type: EXPERIMENTAL
Intervention: victim
Number of subjects: 505
Study 34851219 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 505
Study 33751288 — intervention group
Group type: EXPERIMENTAL
Intervention: Masculine children
Number of subjects: 400
Study 33751288 — intervention group
Group type: EXPERIMENTAL
Intervention: Feminine children
Number of subjects: 400
Study 33751288 — intervention group
Group type: COMPARATOR
Intervention: Control children
Number of subjects: 400
Study 33154793 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyrax expander
Number of subjects: 42
Study 33154793 — intervention group
Group type: COMPARATOR
Intervention: Haas expander
Number of subjects: 42
Study 33589633 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological GDF15
Number of subjects: 0
Study 33589633 — intervention group
Group type: COMPARATOR
Intervention: Endurance exercise (physiological GDF15 induction)
Number of subjects: 0
Study 33377442 — intervention group
Group type: EXPERIMENTAL
Intervention: Good Research for Comparative Effectiveness (GRACE) Checklist
Number of subjects: 0
Study 33377442 — intervention group
Group type: EXPERIMENTAL
Intervention: IMI GetReal RWE Navigator
Number of subjects: 0
Study 33377442 — intervention group
Group type: EXPERIMENTAL
Intervention: Center for Medical Technology Policy (CMTP) RWE Decoder
Number of subjects: 0
Study 33377442 — intervention group
Group type: EXPERIMENTAL
Intervention: CER Collaborative tool
Number of subjects: 0
Study 33377442 — intervention group
Group type: EXPERIMENTAL
Intervention: Real World Evidence Assessments and Needs Guidance (REAdi) tool
Number of subjects: 0
Study 36327755 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-rebreather mask combined with low-flow nasal cannula (NRB + NC)
Number of subjects: 110
Study 36327755 — intervention group
Group type: COMPARATOR
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 110
Study 35958552 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rituximab (600 mg)
Number of subjects: 2
Study 34174084 — intervention group
Group type: EXPERIMENTAL
Intervention: Process Evaluation (PE)
Number of subjects: 6
Study 34174084 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible and pragmatic approaches (e.g., interviews instead of focus groups)
Number of subjects: 6
Study 34916086 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide 240 mg/d
Number of subjects: 1207
Study 34916086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1207
Study 33788458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training and scalp acupuncture at Baihui (GV 20), Sishencong (EX‐HN 1), Zhisanzhen and Niesanzhen, needles retained for 6 hours, treated once a day, 6 times a week for 3 courses of one month each.
Number of subjects: 70
Study 33788458 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training (control group).
Number of subjects: 70
Study 33931919 — intervention group
Group type: COMPARATOR
Intervention: Postoperative surgery alone
Number of subjects: 0
Study 33931919 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil
Number of subjects: 0
Study 32203007 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPA-treated RBC exchange transfusion
Number of subjects: 0
Study 32203007 — intervention group
Group type: COMPARATOR
Intervention: Standard RBC exchange transfusion
Number of subjects: 0
Study 34654929 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug arm
Number of subjects: 70
Study 32966568 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-marketing program focused on the possible consequences of the reporting decision
Number of subjects: 468
Study 32966568 — intervention group
Group type: COMPARATOR
Intervention: Traditional concussion-symptom education based on the NCAA's publication
Number of subjects: 468
Study 32966568 — intervention group
Group type: COMPARATOR
Intervention: Revised symptom education with less clinical delivery
Number of subjects: 468
Study 35500786 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 648
Study 35500786 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose-rate brachytherapy (HDR) monotherapy
Number of subjects: 648
Study 35500786 — intervention group
Group type: COMPARATOR
Intervention: High dose-rate brachytherapy (HDR) boost
Number of subjects: 648
Study 32829654 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein hydrolysate
Number of subjects: 80
Study 32829654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 35469481 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine injection into the temporalis tendon
Number of subjects: 40
Study 35469481 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve growth factor injection into the temporalis tendon
Number of subjects: 40
Study 35469481 — intervention group
Group type: COMPARATOR
Intervention: Nerve growth factor injection
Number of subjects: 40
Study 32155399 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 65
Study 32155399 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal cytoreduction
Number of subjects: 65
Study 32155399 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 65
Study 32155399 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of pelvic pain at presentation
Number of subjects: 65
Study 32155399 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III
Number of subjects: 65
Study 32155399 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of cytoreduction
Number of subjects: 65
Study 32155399 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological subtypes
Number of subjects: 65
Study 32155399 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant treatment
Number of subjects: 65
Study 32155399 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of pelvic pain at diagnosis
Number of subjects: 65
Study 32155399 — intervention group
Group type: EXPERIMENTAL
Intervention: FIGO IIIC stage
Number of subjects: 65
Study 32155399 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate adjuvant treatment
Number of subjects: 65
Study 32155399 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological type of clear cell cancer
Number of subjects: 65